| | | | Doc, I agree with you on 132 backstopping any price collapse in case of negative binary, in fact, I have stated the year's delay might turn out to be a good thing This summer's delay may also prove to be a positive as we are slated to get data in two weeks in Spain. Hopefully we get updated data in all indication before binary. Wall street have ignored 132 so far, because they feel that 132 has to run in a randomized P2. The only way to bypass this is exceptional data, If 132 can achieve a 9 months PFS, in TNBC, it will qualify as a "breakthrough" drug. The last update was from scans in early April, we got 6 mts PFS, however, 56% of patients are still in progression free mode, even if we discount that number by 10%-15% per month we can still hit 9 mts PFS, which will dramatically increase the value of the agent. A price trajectory like Puma Biotech is likely in such a scenario. |
|
